Cargando…

Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line

BACKGROUND: Cowden Syndrome (CS) patients with germ line point mutations in the PTEN gene are at high risk for developing breast cancer. It is believed that cells harboring these mutant PTEN alleles are predisposed to malignant conversion. This article will characterize the biochemical and biologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Gobind, Odriozola, Leticia, Guan, Hong, Kennedy, Colin R, Chan, Andrew M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247870/
https://www.ncbi.nlm.nih.gov/pubmed/22103913
http://dx.doi.org/10.1186/1471-2407-11-490
_version_ 1782220183637590016
author Singh, Gobind
Odriozola, Leticia
Guan, Hong
Kennedy, Colin R
Chan, Andrew M
author_facet Singh, Gobind
Odriozola, Leticia
Guan, Hong
Kennedy, Colin R
Chan, Andrew M
author_sort Singh, Gobind
collection PubMed
description BACKGROUND: Cowden Syndrome (CS) patients with germ line point mutations in the PTEN gene are at high risk for developing breast cancer. It is believed that cells harboring these mutant PTEN alleles are predisposed to malignant conversion. This article will characterize the biochemical and biological properties of a mutant PTEN protein found in a commonly used metastatic breast cancer cell line. METHODS: The expression of PTEN in human breast carcinoma cell lines was evaluated by Western blotting analysis. Cell line MDA-MB-453 was selected for further analysis. Mutation analysis of the PTEN gene was carried out using DNA isolated from MDA-MB-453. Site-directed mutagenesis was used to generate a PTEN E307K mutant cDNA and ectopic expressed in PC3, U87MG, MCF7 and Pten(-/- )mouse embryo fibroblasts (MEFS). Histidine (His)-tagged PTEN fusion protein was generated in Sf9 baculovirus expression system. Lipid phosphatase and ubiquitination assays were carried out to characterize the biochemical properties of PTEN E307K mutant. The intracellular localization of PTEN E307K was determined by subcellular fractionation experiments. The ability of PTEN E307K to alter cell growth, migration and apoptosis was analyzed in multiple PTEN-null cell lines. RESULTS: We found a mutation in the PTEN gene at codon 307 in MDA-MB-453 cell line. The glutamate (E) to lysine (K) substitution rendered the mutant protein to migrate with a faster mobility on SDS-PAGE gels. Biochemically, the PTEN E307K mutant displayed similar lipid phosphatase and growth suppressing activities when compared to wild-type (WT) protein. However, the PTEN E307K mutant was present at higher levels in the membrane fraction and suppressed Akt activation to a greater extent than the WT protein. Additionally, the PTEN E307K mutant was polyubiquitinated to a greater extent by NEDD4-1 and displayed reduced nuclear localization. Finally, the PTEN E307K mutant failed to confer chemosensitivity to cisplatinum when re-expressed in Pten(-/- )MEFS. CONCLUSIONS: Mutation at codon 307 in PTEN C2 loop alters its subcellular distribution with greater membrane localization while being excluded from the cell nucleus. This mutation may predispose breast epithelial cells to malignant transformation. Also, tumor cells harboring this mutation may be less susceptible to the cytotoxic effects of chemotherapeutics.
format Online
Article
Text
id pubmed-3247870
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32478702011-12-30 Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line Singh, Gobind Odriozola, Leticia Guan, Hong Kennedy, Colin R Chan, Andrew M BMC Cancer Research Article BACKGROUND: Cowden Syndrome (CS) patients with germ line point mutations in the PTEN gene are at high risk for developing breast cancer. It is believed that cells harboring these mutant PTEN alleles are predisposed to malignant conversion. This article will characterize the biochemical and biological properties of a mutant PTEN protein found in a commonly used metastatic breast cancer cell line. METHODS: The expression of PTEN in human breast carcinoma cell lines was evaluated by Western blotting analysis. Cell line MDA-MB-453 was selected for further analysis. Mutation analysis of the PTEN gene was carried out using DNA isolated from MDA-MB-453. Site-directed mutagenesis was used to generate a PTEN E307K mutant cDNA and ectopic expressed in PC3, U87MG, MCF7 and Pten(-/- )mouse embryo fibroblasts (MEFS). Histidine (His)-tagged PTEN fusion protein was generated in Sf9 baculovirus expression system. Lipid phosphatase and ubiquitination assays were carried out to characterize the biochemical properties of PTEN E307K mutant. The intracellular localization of PTEN E307K was determined by subcellular fractionation experiments. The ability of PTEN E307K to alter cell growth, migration and apoptosis was analyzed in multiple PTEN-null cell lines. RESULTS: We found a mutation in the PTEN gene at codon 307 in MDA-MB-453 cell line. The glutamate (E) to lysine (K) substitution rendered the mutant protein to migrate with a faster mobility on SDS-PAGE gels. Biochemically, the PTEN E307K mutant displayed similar lipid phosphatase and growth suppressing activities when compared to wild-type (WT) protein. However, the PTEN E307K mutant was present at higher levels in the membrane fraction and suppressed Akt activation to a greater extent than the WT protein. Additionally, the PTEN E307K mutant was polyubiquitinated to a greater extent by NEDD4-1 and displayed reduced nuclear localization. Finally, the PTEN E307K mutant failed to confer chemosensitivity to cisplatinum when re-expressed in Pten(-/- )MEFS. CONCLUSIONS: Mutation at codon 307 in PTEN C2 loop alters its subcellular distribution with greater membrane localization while being excluded from the cell nucleus. This mutation may predispose breast epithelial cells to malignant transformation. Also, tumor cells harboring this mutation may be less susceptible to the cytotoxic effects of chemotherapeutics. BioMed Central 2011-11-21 /pmc/articles/PMC3247870/ /pubmed/22103913 http://dx.doi.org/10.1186/1471-2407-11-490 Text en Copyright ©2011 Singh et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Singh, Gobind
Odriozola, Leticia
Guan, Hong
Kennedy, Colin R
Chan, Andrew M
Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
title Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
title_full Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
title_fullStr Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
title_full_unstemmed Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
title_short Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
title_sort characterization of a novel pten mutation in mda-mb-453 breast carcinoma cell line
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247870/
https://www.ncbi.nlm.nih.gov/pubmed/22103913
http://dx.doi.org/10.1186/1471-2407-11-490
work_keys_str_mv AT singhgobind characterizationofanovelptenmutationinmdamb453breastcarcinomacellline
AT odriozolaleticia characterizationofanovelptenmutationinmdamb453breastcarcinomacellline
AT guanhong characterizationofanovelptenmutationinmdamb453breastcarcinomacellline
AT kennedycolinr characterizationofanovelptenmutationinmdamb453breastcarcinomacellline
AT chanandrewm characterizationofanovelptenmutationinmdamb453breastcarcinomacellline